>

Gilead Sciences Profile

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>GIL</div>

Performance

2 / 100

Odds of Distress

Equity ratings for Gilead Sciences are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting November 23, 2019 and ending today February 21, 2020. Click here to learn more.

Gilead Sciences Profile

Next fiscal quarter end is expected on March 31, 2020. Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. more on Gilead Sciences
Gilead Sciences Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Gilead Sciences SEC Filings
Gilead Sciences SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameGilead Sciences
Chairman and CEOJohn MartinView All
Thematic Classification
Currently Active Investing Idea
  Macroaxis Index
View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Gilead Sciences
Piotroski F Score
Academic score to determine the current strength of Gilead Sciences financial position
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
Financial Strength
Gilead Sciences ability to generate sufficient cash flow to pay bills, repay debt, and make consistent year-to-year profit
Total Debt
Debt Current
Debt Non Current
Long Term Debt to Equity
Debt to Equity Ratio
Return on Investment
Return on Average Assets
Return on Average Equity
Return on Invested Capital
Return on Sales
Earnings per Basic Share
Earnings per Diluted Share
Price to Earnings Ratio
Earnings before Tax
Average Bond Rating: A-Very Good
Profitability
Few selected profitability drivers of Gilead Sciences representing accounts that assess its ability to generate profits relative to its revenue, operating costs, and shareholders' equity
Consolidated Income
Net Income
Net Income Common Stock
Operating Income
Income Tax Expense
Net Income Per Employee
Operating Margin
EBITDA Margin
Gross Margin
Profit Margin
Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 11,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 81.6 B. Gilead Sciences conducts business under Healthcare sector and is part of Drug Manufacturers?General industry. The entity has 1.27 B outstanding shares of which 20.59 M shares are currently shorted by private and institutional investors with about 2.27 trading days to cover. GILEAD SCIENCES currently holds about 25.05 B in cash with 5.65 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 19.79.
Check Gilead Sciences Probability Of Bankruptcy

Ownership Allocation (%)

Gilead Sciences Target Price Odds Analysis

Odds Below 67.01HorizonTargetOdds Above 67.01
79.89%30 days 67.01 19.78%
Based on normal probability distribution, the odds of Gilead Sciences to move above current price in 30 days from now is about 19.78 (This Gilead Sciences probability density function shows the probability of Gilead Sciences Stock to fall within a particular range of prices over 30 days) .

Gilead Sciences Top Holders

Gilead Sciences Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares106.5 M6.9 B
Capital Research Global InvestorsCommon Shares85.1 M5.5 B
View Gilead Sciences Diagnostics

Gilead Sciences Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

Gilead Sciences Against Markets

Did you try this?

Run Focused Opportunities Now

   

Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Module

Gilead Sciences Upcoming and Recent Events

Gilead Sciences Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportMay 7, 2020
Next Earnings ReportAugust 4, 2020
Next Fiscal Quarter EndMarch 31, 2020
Next Fiscal Year EndFebruary 2, 2021
Last Quarter Report DateDecember 31, 2019
Last Earning Anouncement DateMarch 31, 2019

Gilead Sciences Corporate Filings

Gilead Sciences SEC Reporting

Unclassified Corporate Event
Financial Statements and Exhibits. Results of Operations and Financial Condition
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Gilead Sciences Distributions to stockholders

Gilead Sciences Corporate Directors

Gayle Wilson Independent Director
Jacqueline Barton Director
John Madigan Independent Director
Please check Risk vs Return Analysis. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.
Company logos by clearbit